Proton pump inhibitors therapy vs H2 receptor antagonists therapy for XXXX after endoscopy: A meta-analysis.

@entity1 @entity360 @entity353
AIM: To compare the therapeutic effects of proton pump inhibitors vs H2 receptor antagonists for @entity360 in @entity1 after successful endoscopy. METHODS: We searched the Cochrane library, MEDLINE, EMBASE and PubMed for randomized controlled trials until July 2014 for this study. The risk of bias was evaluated by the Cochrane Collaboration's tool and all of the studies had acceptable quality. The main outcomes included mortality, re-bleeding, received surgery rate, blood transfusion units and hospital stay time. These outcomes were estimated using odds ratios (OR) and mean difference with 95% confidence interval (CI). RevMan 5.3.3 software and Stata 12.0 software were used for data analyses. RESULTS: Ten randomized controlled trials involving 1283 @entity1 were included in this review; 678 subjects were in the proton pump inhibitors (PPI) group and the remaining 605 subjects were in the H2 receptor antagonists (H2RA) group. The meta-analysis results revealed that after successful endoscopic therapy, compared with H2RA, PPI therapy had statistically significantly decreased the recurrent bleeding rate (OR = 0.36; 95%CI: 0.25-0.51) and receiving surgery rate (OR = 0.29; 95%CI: 0.09-0.96). There were no statistically significant differences in mortality (OR = 0.46; 95%CI: 0.17-1.23). However, significant heterogeneity was present in both the numbers of @entity1 requiring blood transfusion after treatment [ @entity353 ( @entity353 ), -0.70 unit; 95%CI: -1.64 - 0.25] and the time that @entity1 remained hospitalized [ @entity353 , -0.77 d; 95%CI: -1.87 - 0.34]. The Begg's test (P = 0.283) and Egger's test (P = 0.339) demonstrated that there was no publication bias in our meta-analysis. CONCLUSION: In @entity1 with @entity360 after successful endoscopic therapy, compared with H2RA, PPI may be a more effective therapy.
